Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;37(11):2147-50.
doi: 10.1007/s10529-015-1908-z. Epub 2015 Jul 7.

Molecular pharming's foot in the FDA's door: Protalix's trailblazing story

Tsafrir S Mor  1
Affiliations
Review

Molecular pharming's foot in the FDA's door: Protalix's trailblazing story

Tsafrir S Mor. Biotechnol Lett. 2015 Nov.

Abstract

Objectives: This short commentary examines the factors that led to Food and Drug Administration's approval of the first plant-derived biologic.

Results: In 2012, the first plant-derived protein pharmaceutical (biologic) was approved for commercial use in humans. The product, a recombinant form of human β-glucocerebrosidase marketed as ELELYSO, was developed by Protalix Biotherapeutics (Carmiel, Israel). The foresight to select this particular therapeutic product for development, flawless production pipeline, and serendipity seem to provide the key in explaining how ELELYSO became the first plant-derived biologic to achieve approval by Food and Drug Administration.

Conclusions: While the circumstances that enabled Protalix and its scientists to become the first to arrive at this historic milestone are perhaps unique, it is anticipated that more biologics will follow suit in winning regulatory endorsement.

Keywords: Ebola; FDA-approval; Gaucher’s disease; Molecular pharming; Plant-derived biologics.

PubMed Disclaimer

References

    1. Aggarwal S. What’s fueling the biotech engine--2008. Nat Biotechnol. 2009;27:987–93. - PubMed
    1. Aggarwal SR. What’s fueling the biotech engine-2011 to 2012. Nat Biotechnol. 2012;30:1191–7. - PubMed
    1. Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld D, Mizrachi S, Liberman Y, Freeman A, Zimran A, Galun E. A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation. PLoS One. 2009;4:e4792. - PMC - PubMed
    1. Bashaw ED, Huang SM, Cote TR, Pariser AR, Garnett CE, Burckart G, Zhang L, Men AY, Le CD, Charlab R, Gobburu JV, Lesko LJ. Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov. 2011;10:795–6. - PubMed
    1. Bishop BM. Potential and emerging treatment options for Ebola virus disease. Ann Pharmacother. 2015;49:196–206. - PubMed

Publication types

LinkOut - more resources